Ad

OCUL – Ocular Therapeutix Inc

Compliant

★★★☆☆

Ocular Therapeutix Inc is Shariah compliant. The company’s financials pass three standards and fail in two.

$244,863,169

Market cap

39.99%

Revenue Growth

BUY

Analysts' Rating

Ad

Recommendation Rating

1.86

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 15.71

Low: 5

High: 29

Total Analysts: 7

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocularitching associated with allergic conjunctivitis. Its earlier stage development assets include axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet AMD and other retinal diseases. Its travoprost intracameral implant (OTX-TIC) is under Phase II clinical trial to evaluate the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. It has also completed Phase II clinical trials for cyclosporine intracanalicular insert (OTX-CSI) for the chronic treatment of dry eye disease and dexamethasone intracanalicular insert (OTX-DED) for the short-term treatment of the signs and symptoms of dry eye disease.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses